DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Application
Claims 31-50 are pending and are examined herein.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 31-38, 41-47 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 11,241,467 in view of Asari et al. (US Patent Application 2014/0220063 A1, of record).
The referenced claims recite a method of treating acne by administering a substituted or unsubstituted diindolylmethane and a substituted or unsubstituted retinoic acid based compound.
The referenced claims do not teach a sublingual or buccal route of administration.
Asari et al. teach that 3,3’-diindolylmethane can be formulated into a liquid for sublingual administration (Table 46, example 722; Table 47, example 791; Table 48, example 857).
Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to formulate a composition comprising diindolylmethane for a method of treating acne into a composition that can be administered by a sublingual or buccal route, as taught by Asari et al.
A person of ordinary skill in the art would have been motivated to treat a subject with acne by administering a composition comprising diindolylmethane by a sublingual or buccal route because Asari et al. teach that diindolylmethane is known to be administered sublingually as a liquid. Therefore, one of ordinary skill in the art would have had a reasonable expectation of success in treating acne by administering diindolylmethane and vitamin A palmitate by a sublingual or buccal route.
Claims 31-50 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 11,331,303.
Both sets of claims recite a method of treating a skin condition in a subject by administering a composition comprising diindolylmethane and vitamin A palmitate, wherein the composition is administered by a sublingual or buccal route.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
The factual inquiries set forth in Graham vs John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
Claims 31-50 are rejected under 35 U.S.C. 103(a) as being obvious over Alpert et al. (WO 2012/130698 A1, of record) in view of Asari et al. (US Patent Application 2014/0220063 A1, of record).
The instant claims are directed to a method of treating a skin condition in a subject by administering a composition comprising diindolylmethane and vitamin A palmitate, wherein the composition is administered by a sublingual or buccal route.
Alpert et al. teach a method of treating a skin condition (claim 32) by administering a substituted or unsubstituted diindolylmethane (claim 1) and vitamin A palmitate (claim 8, figure 1), wherein the skin condition is acne (claim 18). Diindoylmethane can be in micro-encapsulated particle form. Pharmaceutically acceptable excipients are also taught (page 13, third and fourth paragraphs). A preferred daily dosage is 18-75 mg (bridging paragraph on pages 11-12). Patients were administered this composition over the course of 3 months (entire page 17). Oral or topical administration, in the form of a tablet, capsule, gel, cream, or ointment, is taught (claims 19-20), however, any route of administration may be used (page 11, first full paragraph). This composition is adapted for increased bioavailability (claim 23) or synergy (page 2, first paragraph).
However, Alpert et al. fail to disclose a sublingual or buccal route of administration.
Asari et al. teach that 3,3’-diindolylmethane can be formulated into a liquid for sublingual administration (Table 46, example 722; Table 47, example 791; Table 48, example 857).
Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to formulate a composition comprising diindolylmethane and vitamin A palmitate for a method of treating acne, as taught by Alpert et al., into a composition that can be administered by a sublingual or buccal route, as taught by Asari et al.
A person of ordinary skill in the art would have been motivated to treat a subject with acne by administering a composition comprising diindolylmethane and vitamin A palmitate by a sublingual or buccal route because Alpert et al. teach that any known route of administration may be used, in general. Furthermore, Asari et al. teach that diindolylmethane is known to be administered sublingually as a liquid. Therefore, one of ordinary skill in the art would have had a reasonable expectation of success in treating acne by administering diindolylmethane and vitamin A palmitate by a sublingual or buccal route.
The Examiner notes that the limitations drawn to increased bioavailability are obvious to occur in vivo since these are mechanism of action that will occur when the same compounds are being administered to the same subject at the same dosage.
Applicant’s arguments herein are related to the mechanism of action of an agent in the treatment. Note that the mechanism of action of an agent in the treatment, by itself, does not have a bearing on the patentability of the invention if the method steps are already known even though applicant has proposed or claimed the mechanism. Applicant’s recitation of a new mechanism of action for the prior art method will not, by itself, distinguish the instant claims over the prior art teaching the same or nearly the same method steps.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free).
/Yong S. Chong/Primary Examiner, Art Unit 1623